| Literature DB >> 16696864 |
Suzana M Lobo1, Francisco R Lobo, Carlos A Polachini, Daniela S Patini, Adriana E Yamamoto, Neymar E de Oliveira, Patricia Serrano, Helder S Sanches, Marco A Spegiorin, Marcio M Queiroz, Antonio C Christiano, Elisangela F Savieiro, Paula A Alvarez, Silvia P Teixeira, Geni S Cunrath.
Abstract
INTRODUCTION: Preventing perioperative tissue oxygen debt contributes to a better postoperative recovery. Whether the beneficial effects of fluids and inotropes during optimization of the oxygen delivery index (DO2I) in high-risk patients submitted to major surgeries are due to fluids, to inotropes, or to the combination of the two is not known. We aimed to investigate the effect of DO2I optimization with fluids or with fluids and dobutamine on the 60-day hospital mortality and incidence of complications.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16696864 PMCID: PMC1550955 DOI: 10.1186/cc4913
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Risk scoring system (adapted from American College of Cardiology/American Heart Association guidelines)
| Score | Risk factor |
| High-risk surgery (1 point) | Gastrectomy |
| Minor clinical predictor (1 point) | Diabetes (defined as standard taking medication or not) |
| Intermediate clinical predictor (2 points) | Age (>60 years) |
| Major clinical predictor (3 points) | Angina (class III or IV, Canadian Cardiovascular Society Classification) Severe arrhythmias (advanced heart block, ventricular arrhythmia in the presence of cardiopathy or supraventricular arrhythmia with tachycardia) Severe valvopathy (severe valvular regurgitation with reduced left ventricular function) |
Figure 1Treatment algorithm. MAP, mean arterial pressure; PAOP, pulmonary artery occlusion pressure; Ht, hematocrit; SaO2, arterial oxygen saturation; DO2I, oxygen delivery index; RBC, red blood cells; CI, cardiac index.
Baseline characteristics of patients in the volume group and the dobutamine group
| Volume group | Dobutamine group | |
| Number of patients | 25 | 25 |
| Male (%) | 69 | 76 |
| Age | 69.9 ± 8.4 | 67.6 ± 7.5 |
| Acute Physiology and Chronic Health Evaluation II score | 14.4 ± 6.2 | 12.4 ± 6.5 |
| Risk Scoring System (points) | 4.25 ± 1.22 | 4.44 ± 1.53 |
| Aged > 60 years | 23 (92%) | 20 (80%) |
| Cancer | 24 (96%) | 25 (100%) |
| Arterial hypertension | 16 (64%) | 13 (52%) |
| Coronary artery disease | 6 (24%) | 5 (20%) |
| Diabetes mellitus | 5 (20%) | 2 (8%) |
| Chronic obstructive pulmonary disease | 4 (16%) | 0 (0%) |
| Arrhythmia | 3 (12%) | 2 (8%) |
| Cerebral vascular accident | 1 (4%) | 0 (0%) |
| Compensated heart failure | 2 (8%) | 3 (12%) |
| Chronic renal failure | 0 (0%) | 1 (4%) |
| Type of surgery | ||
| Colorectal | 9 | 5 |
| Hepatobiliary | 1 | 1 |
| Duodenopancreatectomy | 2 | 5 |
| Esofagectomy | 1 | 3 |
| Gastrectomy | 6 | 5 |
| Urology | 5 | 4 |
| Other | 1 | 2 |
Therapeutic interventions and changes in perfusion variables during optimization
| Volume group | Dobutamine group | |
| Intraoperatively | ||
| Operation time (min) | 315 ± 109 | 331 ± 132 |
| Total volume (l/hour) | 1.31 ± 0.54 (0.97/1.21/1.54) | 1.35 ± 0.43 (1.05/1.29/1.65) |
| Red blood cells (ml) | 609 ± 244 (480/600/600) | 713 ± 458 (500/600/650) |
| Number of transfused patients (%) | 11 (44%) | 12 (48%) |
| Dobutamine doses (μg/kg/minute) | 3.5 ± 0.7 | 5.5 ± 1.8 |
| Dobutamine (number of patients) | 2 (8%) | 25 (100%)* |
| Initial serum lactate (mEq/l) | 1.3 ± 0.6 | 1.3 ± 0.5 |
| Final serum lactate (mEq/l) | 1.7 ± 0.7 | 1.9 ± 0.9 |
| Initial mixed venous oxygen saturation | 83 ± 4 | 81 ± 6 |
| Final mixed venous oxygen saturation | 86 ± 4 | 86 ± 7 |
| Number of goal-achievers | 7 (28%) | 21 (84%)* |
| Intensive care unit | ||
| Total volume (l/hours) | 0.29 ± 0.12 | 0.28 ± 0.18 |
| Red blood cells (ml) | 1064 ± 684 (450/600/900) | 650 ± 226* (600/600/600) |
| Number of transfused patients (%) | 7 (28%) | 6 (24%) |
| Dobutamine doses (μg/kg/minute) | 5.7 ± 2.3 | 6.1 ± 3.4 |
| Dobutamine (number of patients) | 6 (24%) | 20 (80%)* |
| Sodium nitroprusside | 6 (24%) | 2 (8%) |
| Initial serum lactate (mEq/l) | 2.5 ± 1.6 | 2.2 ± 0.8 |
| Final serum lactate (mEq/l) | 1.9 ± 2.0 | 1.3 ± 0.4 |
| Initial mixed venous oxygen saturation | 76 ± 13 | 78 ± 9 |
| Final mixed venous oxygen saturation | 78 ± 9 | 77 ± 8 |
| Number of goal-achievers | 16 (64%) | 22 (88%)* |
Data presented as the absolute value (%) or as the mean ± standard deviation. *P < 0.05 versus volume group.
Figure 2Oxygen delivery index during surgery and postoperatively. Oxygen delivery index (DO2I) during surgery and postoperatively for the volume group (●) and the dobutamine group (■). *P < 0.05 versus volume group, #P < 0.05 versus baseline. Results presented as the mean and standard error or the mean. 0, preoperative; 1, 30 min intraoperatively; 2, 2 hours intraoperatively; 3, 4 hours intraoperatively; 4, 6 hours intraoperatively; 5, 8 hours intraoperatively; 6, 0 hours postoperatively; 7, 4 hours postoperatively; 8, 8 hours postoperatively; 10, 12 hours postoperatively; 11, 16 hours postoperatively; 12, 24 hours postoperatively.
Hemodynamic and perfusion variables during surgery and postoperatively
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | |
| Cardiac index (l/minute/m2) | |||||||||||||
| Volume group | 3.6/1.1 (25) | 3.2/1.1 (25) | 3.3/0.8 (22) | 3.5/0.6 (15) | 3.4/0.8 (13) | 3.9/0.8 (4) | 2.5/0.7 | 2.9/0.8 | 3.1/0.9 | 3.2/0.8 | 3.5/0.9 | 3.8/1.2 | 3.7/0.6 |
| Dobutamine group | 3.4/0.7 (25) | 3.0/0.8 (25) | 4.0/1.0*# (22) | 4.6/1.2* # (13) | 4.5/0.5* # (10) | 4.6/0.7# (8) | 3.0/0.9* | 3.6/1.0* | 3.8/1.0* | 3.9/0.8* # | 3.9/0.7# | 4.0/0.8# | 4.0/0.9# |
| Left ventricular stroke work index (g/m/m2) | |||||||||||||
| Volume group | 65/22 (25) | 43/12# (25) | 43/12# (22) | 41/13# (15) | 46/12# (10) | 45/11 (4) | 37/13# | 37/15# | 41/23# | 42/28# | 46/18# | 45/22# | 42/18# |
| Dobutamine group | 58/15 (25) | 43/13# (25) | 49/17 (22) | 48/9* # (13) | 50/14 (10) | 49/18 (8) | 39/18# | 43/20# | 41/19# | 42/21# | 41/20# | 43/17# | 42/16# |
| Pulmonary artery occlusion pressure (mmHg) | |||||||||||||
| Volume group | 12/4.3 (25) | 12/4.3 (25) | 10/3.0 (22) | 10/3.0 (14) | 11/3.3 (12) | 8/1.1 (3) | 9/4.1 | 11/4.7 | 13/4.5 | 11/4.6 | 12/3.5 | 12/3.3 | 12/3.9 |
| Dobutamine group | 11/4.0 (25) | 12/3.3 (25) | 10/2.9 (22) | 9/2.5 (13) | 8/1.6* # (10) | 10/1.1 (8) | 9/3.3 | 10/3.9 | 11/3.5 | 11/4.4 | 11/4.4 | 11/3.7 | 12/3.3 |
| Lactate (mEq/l) | |||||||||||||
| Volume group | 1.3/0.6 | 1.3/0.6 | 1.2/0.5 | 1.7/0.6 | 2.5/1.6 | 2.8/2.0 | 2.5/1.6 | 2.8/1.9 | 2.0/1.9 | 2.2/2.0 | 2.1/2.4 | 1.9/1.8 | 1.9/2.0 |
| Dobutamine group | 1.3/0.5 | 1.4/0.8 | 1.9/0.6 | 1.2/0.4 | 2.2/0.8 | 1.9/0.8 | 2.2/0.8 | 1.9/0.8 | 1.6/0.6 | 1.6/0.8 | 1.7/0.8 | 1.3/0.8 | 1.3/0.4 |
| Mixed venous oxygen saturation (%) | |||||||||||||
| Volume group | 83/4 | - | 86/3 | 86/5 | 86/5 | 86/2 | 76/13 | 73/11 | 76/15 | 77/10 | 77/10 | 77/11 | 78/9 |
| Dobutamine group | 81/6 | - | 86/2 | 87/5 | 85/6 | 83/11 | 78/9 | 80/10 | 80/9 | 77/11 | 79/7 | 77/8 | 77/8 |
Results presented as mean/standard deviation. 0, preoperative; 1, 30 minutes intraoperatively; 2, 2 hours intraoperatively; 3, 4 hours intraoperatively; 4, 6 hours intraoperatively; 5, 8 hours intraoperatively; 6, 0 hours postoperatively; 7, 4 hours postoperatively; 8, 8 hours postoperatively; 10, 12 hours postoperatively; 11, 16 hours postoperatively; 12, 24 hours postoperatively. *P < 0.05 versus volume group, #P < 0.05 versus baseline.
Outcome
| Volume group | Dobutamine group | |
| Cardiovascular complications | ||
| Acute heart failure | 2 | 0 |
| Pulmonary edema | 8 | 3 |
| Acute myocardial infarction | 0 | 1 |
| Cardiac arrhythmia | 2 | 0 |
| Mesenteric infarction | 1 | 0 |
| Number of patients with cardiovascular complications (%) | 13 (52%) | 4 (16%)* |
| Infectious complications | ||
| Pneumonia | 5 | 7 |
| Peritonitis | 3 | 3 |
| Urinary tract infection | 1 | 2 |
| Fistula | 1 | 2 |
| Severe sepsis/septic shock | 7 | 4 |
| Number of patients with infectious complications (%) | 7 (28%) | 12 (48%) |
| Other complications | ||
| Postoperative bleeding | 1 | 0 |
| Upper gastrointestinal bleeding | 0 | 1 |
| Acute renal failure | 3 | 1 |
| Acute respiratory failure | 5 | 2 |
| Number of patients with other complications (%) | 9 (36%) | 4 (16%) |
| Total number of complications | 39 | 26 |
| Number of patients with complications (%) | 17(68%) | 14(56%) |
| Number of achievers with complications (%) | 14 (74%) | 14 (58%) |
| C-reactive protein on day 1 (mg/dl) | 18 (11-23) | 13 (10-18) |
| Median duration of intensive care unit stay (days) | 3 (2.0-6.0) | 3(3.0-8.5) |
| Median duration of hospital stay (days) | 14 (8.5-8.5) | 20 (14.5-32) |
| Mortality rate | ||
| 28 days | 5 (20%) | 2 (8%) |
| 60 days | 7 (28%) | 2 (8%) |
Data presented as the absolute value (%) or as the median (interquartile range). *P < 0.05 versus volume group.